Shares: Drug cure for depression: Quentin Lumsden prescribes six healthcare stocks set for recovery

IF THE stock market consisted entirely of healthcare stocks, and the way things are going it sometimes seems as though it soon will, investors would have a very different perspective. Instead of a grim bear market they would see a dramatic bull market, which had paused for breath in the first half of 1991 but now seems to be picking up steam again. My guess is that now is a good time to climb aboard once more.

One problem with the leading healthcare stocks is that they are much favoured by institutional investors and tend to have heavyweight share prices.

In terms of its price-earnings ratio, the cheapest of the six international drug shares I have selected for my mini-portfolio is the Swiss group Roche, which is on a prospective p/e for 1993 of under 13, according to the analyst Andrew Tivenen, of James Capel. But one share in Roche costs a jaw-dropping SFr3,380 (pounds 1,368).

Fortunately, heavyweight prices are no bar to a sizzling performance. Roche shares have climbed four-fold from their levels in the mid-1980s. The same goes for the other shares in my selection. Glaxo at 749p is up five-fold; Wellcome, at 826p, is up 6.5 times. The world's leading drug company, Merck, at dollars 48.25 (pounds 24.14), is up 10 times in dollar terms but nearer 5.5 times for sterling-based investors. Pfizer, at dollars 79.62, also based in the US, was a slow starter in the 1980s, but new drugs have boosted it around 2.5 times in sterling. Lastly, the Swedish company Astra, at Kr535 for the 'A' shares, has grown fastest of all: 8.5 times in sterling terms.

The key attraction of these great healthcare companies is their ability to sustain strong growth in earnings despite recession. The analysts at James Capel suggested the following medium-term growth rates for my selection: Glaxo 14 per cent, Wellcome 20 per cent, Merck 18, Pfizer 19, Astra 25-30 and Roche 20. That looks highly attractive in a world where investors are coming to terms with the prospect that the global economy may stay becalmed into the mid-1990s. A big change in this decade is that the pronounced weakness of the dollar is no longer seen as a negative for European drug stocks, even though they all make a substantial proportion of their sales in the US.

One analyst, Paul Woodhouse at Smith New Court, says observation almost suggests these shares flourish when the dollar is weak. This could be because American investors like to buy strong-currency stocks.

Nor are profits as adversely affected as in the past. Wellcome and other companies manufacture in the US so that they do not have the problem of trying to sell into the US from a high-cost base. Glaxo sources heavily from dollar-bloc areas such as Singapore.

Furthermore, manufacturing costs are only about 16 per cent of final selling prices. Twice as important are sales and marketing costs incurred in the US for sales made there.

A combination of investors neglecting drug shares and general gloom in stock markets has made these pharmaceuticals relatively cheap by historic standards. Astra, for example, has a spectacular portfolio of drugs. Its world-beating ulcer preparation, Losec, has overtaken SmithKline's Tagamet and is second only to Glaxo's Zantac. Yet on analyst Andrew Tivenen's estimates, Astra is on a prospective p/e of 16 on 1993 earnings per share, and could well continue to grow rapidly.

Shares in Wellcome, almost equally fast-growing, have been depressed by the huge shares sale, and the p/e for the year to 31 August next could be below 18. These are undemanding valuations for some of the most exciting and reliable growth stocks.

(Photograph omitted)

Start your day with The Independent, sign up for daily news emails
newsAnother week, another dress controversy on the internet
Life and Style
Scientist have developed a test which predicts whether you'll live for another ten years
Life and Style
Marie had fake ID, in the name of Johanna Koch, after she evaded capture by the Nazis in wartime Berlin
historyOne woman's secret life as a Jew in wartime Berlin
news... and what your reaction to the creatures above says about you
ebooksA special investigation by Andy McSmith
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Ashdown Group: Junior Application Support Analyst - Fluent German Speaker

£25000 - £30000 per annum + benefits: Ashdown Group: A global leader operating...

Recruitment Genius: Customer Service Advisor

£15000 - £16000 per annum: Recruitment Genius: A Customer Service Advisor is r...

Ashdown Group: Trainee Consultant - Surrey / South West London

£22000 per annum + pension,bonus,career progression: Ashdown Group: An establi...

SThree: HR Benefits Manager

£40000 - £50000 per annum + pro rata: SThree: SThree Group have been well esta...

Day In a Page

Syrian conflict is the world's first 'climate change war', say scientists, but it won't be the last one

Climate change key in Syrian conflict

And it will trigger more war in future
How I outwitted the Gestapo

How I outwitted the Gestapo

My life as a Jew in wartime Berlin
The nation's favourite animal revealed

The nation's favourite animal revealed

Women like cuddly creatures whilst men like creepy-crawlies
Is this the way to get young people to vote?

Getting young people to vote

From #VOTESELFISH to Bite the Ballot
Poldark star Heida Reed: 'I don't think a single bodice gets ripped'

Poldark star Heida Reed

'I don't think a single bodice gets ripped'
The difference between America and Israel? There isn’t one

The difference between America and Israel? There isn’t one

Netanyahu knows he can get away with anything in America, says Robert Fisk
Families clubbing together to build their own affordable accommodation

Do It Yourself approach to securing a new house

Community land trusts marking a new trend for taking the initiative away from developers
Head of WWF UK: We didn’t send Cameron to the Arctic to see green ideas freeze

David Nussbaum: We didn’t send Cameron to the Arctic to see green ideas freeze

The head of WWF UK remains sanguine despite the Government’s failure to live up to its pledges on the environment
Author Kazuo Ishiguro on being inspired by shoot-outs and samurai

Author Kazuo Ishiguro on being inspired by shoot-outs and samurai

Set in a mythologised 5th-century Britain, ‘The Buried Giant’ is a strange beast
With money, corruption and drugs, this monk fears Buddhism in Thailand is a ‘poisoned fruit’

Money, corruption and drugs

The monk who fears Buddhism in Thailand is a ‘poisoned fruit’
America's first slavery museum established at Django Unchained plantation - 150 years after slavery outlawed

150 years after it was outlawed...

... America's first slavery museum is established in Louisiana
Kelly Clarkson: How I snubbed Simon Cowell and become a Grammy-winning superstar

Kelly Clarkson: How I snubbed Simon Cowell and become a Grammy-winning superstar

The first 'American Idol' winner on how she manages to remain her own woman – Jane Austen fascination and all
Tony Oursler on exploring our uneasy relationship with technology with his new show

You won't believe your eyes

Tony Oursler's new show explores our uneasy relationship with technology. He's one of a growing number of artists with that preoccupation
Ian Herbert: Peter Moores must go. He should never have been brought back to fail again

Moores must go. He should never have been brought back to fail again

The England coach leaves players to find solutions - which makes you wonder where he adds value, says Ian Herbert
War with Isis: Fears that the looming battle for Mosul will unleash 'a million refugees'

The battle for Mosul will unleash 'a million refugees'

Aid agencies prepare for vast exodus following planned Iraqi offensive against the Isis-held city, reports Patrick Cockburn